BioMarin Pharmaceutical Inc.
NASDAQ Global SelectCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Alexander Hardy
- Full Time Employees
- 3,221
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 770 Lindaro Street San Rafael CA United States of America 94901
- IPO Date
- Jul 26, 1999
- CIK
- 0001048477
- Website
- biomarin.com
- Similar Companies
- Business
- BioMarin Pharmaceutical Inc. is a global biotechnology company specializing in the development and commercialization of innovative therapies for rare genetic diseases and serious medical conditions. Founded in 1997 and headquartered in San Rafael, California, BioMarin offers a portfolio of approved products including VOXZOGO for achondroplasia and hypochondroplasia; ROCTAVIAN for severe hemophilia A; BRINEURA for Batten disease; and ALDURAZYME for mucopolysaccharidosis I. The company’s product pipeline includes advanced investigational therapies such as BMN 351 for Duchenne muscular dystrophy, BMN 349 for alpha-1 antitrypsin deficiency-associated liver disease, and BMN 333 for multiple growth disorders. BioMarin employs multiple treatment modalities including enzyme replacement therapies, oligonucleotide therapeutics, and gene therapies. Recent major developments include BioMarin’s acquisition of Inozyme Pharma in mid-2025 for approximately $270 million, which expanded BioMarin’s portfolio with INZ-701, a late-stage enzyme replacement therapy in Phase 3 development targeting ENPP1 deficiency, a rare genetic disorder affecting blood vessels and connective tissues. Additionally, BioMarin advanced its pivotal Phase 3 clinical trial for VOXZOGO in hypochondroplasia with topline data expected in 2026 and a potential product launch in 2027. The company also strengthened its research capabilities through collaborations such as the partnership with Deep Genomics to apply artificial intelligence for oligonucleotide drug discovery. In 2023 and 2024, BioMarin focused its R&D strategy by prioritizing three key clinical assets and discontinuing four earlier-stage candidates, accelerating the pace of new drug filings and advancing pipeline productivity. BioMarin operates primarily in the rare disease biopharmaceutical sector with a focus on genetic and lysosomal storage disorders, serving patients across North America, Europe, and other global markets. The company integrates research, development, manufacturing, and commercialization functions, leveraging scientific expertise to bring first- or best-in-class genetic therapies to market. BioMarin’s efforts are supported by strategic alliances and a growing portfolio of proprietary products and clinical-stage candidates aimed at addressing high unmet medical needs in genetic diseases.
Is BioMarin Pharmaceutical (BMRN) Outperforming Other Medical Stocks This Year?
5 Undervalued Price-to-Book Stocks Worth Buying in August
BMRN vs. ILMN: Which Stock Is the Better Value Option?
Wall Street Analysts See a 28.2% Upside in BioMarin (BMRN): Can the Stock Really Move This High?
Why BioMarin Pharmaceutical (BMRN) is a Top Value Stock for the Long-Term
BioMarin Pharmaceutical Inc. (BMRN) Presents at Canaccord Genuity's 46th Annual Growth Conference Transcript
BioMarin Targets Faster Deleveraging as Amicus Deal Expands Rare-Disease Growth
BioMarin to Participate at the Canaccord Genuity 46th Annual Growth Conference on Wednesday, August 12, 2026, at 8:00AM ET in Boston
BMRN Stock Up as Q2 Earnings Beat on Sales Growth, 2026 Outlook Raised
BioMarin Pharmaceutical Inc. (BMRN) Q2 2026 Earnings Call Transcript
Compared to Estimates, BioMarin (BMRN) Q2 Earnings: A Look at Key Metrics
BioMarin Pharmaceutical Q2 Earnings Call Highlights
BioMarin Pharmaceutical (BMRN) Surpasses Q2 Earnings and Revenue Estimates
BioMarin Reports Second Quarter 2026 Financial and Operating Results
Amundi Cuts Position in BioMarin Pharmaceutical Inc. $BMRN
BioMarin to Host Second Quarter 2026 Financial Results Conference Call and Webcast on Thursday, August 6, 2026, at 4:30pm ET
Analysts Estimate BioMarin Pharmaceutical (BMRN) to Report a Decline in Earnings: What to Look Out for
BioMarin and n-Lorem Foundation Enter Early Research Collaboration to Develop Potential First-in-Disease Medicine for Newly Identified ReNU Syndrome
Bank of New York Mellon Corp Sells 631,362 Shares of BioMarin Pharmaceutical Inc. $BMRN
BioMarin: Commercial Infrastructure Is The Hidden Growth Asset